Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL: patient age and overall survival rate

DLBCL is the most common aggressive non-Hodgkin's lymphoma (NHL), comprising approximately 37% of all NHLs (Table 1).1

  • Some patients either relapse after treatment or have primary refractory disease.4 Extensive research to try to help improve outcomes for these patients is ongoing5

  • Although differential treatment based on prognostic markers is not yet a viable option, this approach is under continued exploration and may impact how treatments are used in the future5-7

Table 1. Relative frequencies of B-cell lymphoma subtypes in adults1

Mature B-Cell neoplasms

Percentage of total cases*

Diffuse large B-cell lymphoma 37
Follicular lymphoma 29
Chronic lymphocytic leukemia/small lymphoma 12
Extranodal marginal zone B-cell lymphoma of MALT (MALT lymphoma) 9
Mantle cell lymphoma 7
Primary mediastinal large B-cell lymphoma 3
Nodal marginal zone lymphoma 2
Lymphoplasmacytic lymphoma 1.4
Splenic marginal zone lymphoma 0.9
Burkitt lymphoma/leukemia 0.8

*These figures underestimate the incidence of chronic lymphocytic leukemia/small lymphocytic lymphoma, as only patients presenting clinically with lymphoma were included.